Month: September 2026

CarGurus brings its predictive intelligence to VIN-level marketing, helping dealers boost the right vehicles at the right time to protect margin

BOSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) — CarGurus (Nasdaq: CARG), the No. 1 most visited automotive shopping site in the U.S.², announced details on the latest addition to its dealer platform: VINMax, which extends CarGurus’ consumer demand data and AI-powered predictive intelligence into marketing for the first time. Dealers are getting more listing views, more leads, and faster turn time with VINMax handling the targeting and promotion decisions automatically based on CarGurus’ real-time supply and demand data.

“VINMax is one of CarGurus’ fastest-growing product launches, a signal of the value it provides dealers in maintaining healthy inventory and strong margins,” said Ben Kasdon, Vice President of Dealer Product Management at CarGurus. “Using live market data, it determines where extra visibility can make the biggest difference so dealers can act earlier on VINs at risk of aging while making the most of demand for their strongest inventory.”

CarGurus’ Intelligence Comes to Marketing

VINMax expands CarGurus’ growing dealer solutions across inventory, marketing, lead conversion, and data. Built on the same data and intelligence architecture as PriceVantage and Shopper Signals, VINMax is the first CarGurus product to bring automated, predictive intelligence to marketing.

“Our solutions complement each other to give dealers a more intelligent toolkit across their workflow,” Kasdon added. “PriceVantage identifies when a price change can maximize margin on a high-demand vehicle, or improve performance on slow-moving inventory. When a vehicle is priced right, VINMax determines where more visibility can help drive a sale. Shopper Signals then flags the shoppers most likely to buy. Together, they help dealers act earlier and more decisively to protect and grow margin.”

Using CarGurus’ proprietary marketplace data, VINMax identifies VINs that would benefit most from extra exposure and promotes them automatically on CarGurus and through off-site channels. Vehicles with strong demand get maximized to capture full value at peak interest, while VINMax catches underperforming inventory early, using consumer demand signals to boost high-potential VINs before they age.

An analysis of VINMax-boosted listings on CarGurus shows the impact:

• Vehicles sold 9 days faster than comparable non-boosted listings, a 23% improvement in turn time¹
• Listings also generated 34% more daily leads than comparable non-boosted listings³

To learn more about VINMax, visit: dealers.cargurus.com/vinmax

About CarGurus, Inc.
CarGurus (Nasdaq: CARG) is the leading multinational automotive platform helping consumers and dealers confidently buy and sell vehicles. Founded in 2006 with a mission to bring more trust and transparency to car shopping, CarGurus is the No. 1 visited automotive shopping site in the U.S.¹ with the largest selection of inventory and network of dealers.⁴ CarGurus’ unmatched selection, trusted automotive insights, and data-driven products and solutions support each shopper’s journey — from online research and shopping to in-dealership decisions — to empower them at every step. And, by translating data from billions of monthly site interactions, CarGurus provides dealers a personalized, predictive intelligence platform with software solutions that helps them run their businesses more efficiently and profitably at all stages of inventory acquisition and pricing, marketing, and conversion to sale.

CarGurus operates online marketplaces in the U.S., U.K., and Canada. The company’s network of brands includes PistonHeads, the largest online motoring community in the U.K.⁵, and Autolist, a U.S.- based online marketplace.

To learn more about CarGurus, visit www.cargurus.com.

¹Based on the median time to sale for 10.3K listings boosted by VINMax on CarGurus (not including Facebook) vs. 24K similar never-boosted listings between 2/1/26- 7/13/26
²Similarweb: Traffic and Engagement Report (Cars.com, Autotrader.com, TrueCar.com, CARFAX.com
Listings (defined as CARFAX.com Total Visits minus Vehicle History Reports)), Q2 2026, U.S.
³Based on leads per day for 10.3K listings boosted by VINMax on CarGurus (not including Facebook) vs. 24K similar never-boosted listings between 2/1/26- 7/13/26
⁴Compared to Autotrader.com, Cars.com, TrueCar.com, and CARFAX (Joreca as of June 30, 2026)
⁵Similarweb: Traffic Insights, Q2 2026, U.K.

CarGurus^® and Autolist^® are each a registered trademark of CarGurus, Inc., and PistonHeads^® is a registered trademark of CarGurus Ireland Limited in the U.K. and the European Union. All other product names, trademarks, and registered trademarks are property of their respective owners.

© 2026 CarGurus, Inc., All Rights Reserved.

Media Contact:
Maggie Meluzio
Director, Public Relations & External Communications
pr@cargurus.com

Investor Contact:
Kirndeep Singh
Vice President, Head of Investor Relations
investors@cargurus.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ebf8504d-aaf1-4ea5-a8a4-b1f4e0ada458

Proposed acquisition would bring a gold-backed decentralized financial ecosystem, including decentralized financial infrastructure targeting retail, institutional, and blockchain markets.

• A retail and institutional platform designed for the rapidly growing stablecoin industry, delivering compliance-focused infrastructure for payments, yield, lending and open-ecosystem, industry-wide decentralized financial applications.
• Institutional gold-based infrastructure spanning gold as a currency, gold-collateralized USD products and gold-backed financial products, anchored to an Ethereum-based Layer 2 network designed as a stable foundation for the next generation of industry products.
• Proprietary yield engines designed to power institutional products targeting competitive returns by bridging traditional and decentralized markets.

NEWPORT BEACH, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) — Amaze Holdings, Inc. (NYSE American: AMZE) (“Amaze” or the “Company”) today announced it has entered into a binding Letter of Intent (“LOI”) to acquire the assets of BullionFX, including its core platform Alchemy (collectively, the “BullionFX Assets”), for stock valued at approximately $155 million.

The BullionFX Assets comprise the technology, infrastructure and intellectual property behind a blockchain financial ecosystem built around auditable physical gold. If completed, the acquisition would mark a strategic expansion for Amaze beyond creator commerce and into gold-backed digital-asset infrastructure. The transaction comes amid a broad resurgence in cryptocurrency markets, rapid growth in volume within the stablecoin industry, renewed institutional engagement with digital assets, and continued strength in gold as a long-established store of value. Adjusted stablecoin transaction volume hit $1.79 trillion in June 2026, up 125% year on year, according to Visa Onchain Analytics (Allium).

“Crypto’s renewed momentum and gold’s enduring role as a store of value have opened a rare window for infrastructure built on both,” said Joel Krutz, Interim Chief Executive Officer of Amaze. “Alchemy is a full-stack, gold-backed financial ecosystem, and we believe bringing it into the public markets can create meaningful long-term value for our stockholders.”

The acquisition gives Amaze the technology, infrastructure and intellectual property behind a comprehensive decentralized finance (DeFi) ecosystem in which every unit of digital value is tied to physical gold held by independent custodians. The platform’s architecture supports lending and borrowing protocols, yield products, cross-chain interoperability, and an Ethereum-based Layer 2 network that links traditional and decentralized finance while offering the rapidly growing market of gold- and USD-backed stablecoins users’ broad functionality, including access to yield opportunities.

Following closing, Amaze intends to prioritize activation of the self-custody retail wallet and yield engines and, as an initial institutional application, to pursue a listed Stable Asset Treasury (“SAT”) vehicle for gold and USD, subject to applicable regulatory approvals.

“We have seen traditional financial markets adopt blockchain, and more recently stablecoins, as a direct result of retail users seeking more control, custody, and transferability of their own assets. We believe traditional finance will increasingly bridge with decentralized finance to extract the ideal attributes of both industries. Alchemy is well-positioned to compete in bringing to market a range of bridged traditional and decentralized financial products to introduce innovative financial offerings on a retail and institutional level while seeking to mitigate certain risks associated with traditional stablecoin models,” said Stephen Moss, Founder, BullionFX. “Joining a publicly listed company gives Alchemy the access and institutional credibility to accelerate our mission. That mission is a stable, transparent financial ecosystem for retail users that bridges traditional and decentralized finance.”

INSIDE THE ALCHEMY PLATFORM

$GOLD, Backed by Physical Gold. Alchemy’s core $GOLD token is designed to be backed one-to-one by vaulted, independently custodied and audited physical gold, with reserves intended to be subject to real-time attestation through third-party, institutional-grade audit mechanisms. $GOLD is designed to serve as the network’s settlement asset, combining the stability of a hard asset with the speed and transparency of blockchain settlement.

Built for the Stablecoin Industry. Alchemy is a retail and institutional platform designed for the rapidly growing stablecoin industry. Its compliance-focused architecture is built to support gold-linked payments, yield, lending and borrowing, cross-chain interoperability and open-ecosystem DeFi applications that third-party developers can build on.

Institutional Gold Infrastructure on Ethereum Layer 2. For institutions, Alchemy provides gold-based infrastructure spanning gold as a currency, gold-collateralized USD products and gold-backed financial products. Running on an Ethereum-based Layer 2 network, it is designed to bring gold’s stability on-chain as a foundation for future industry products.

Proprietary Yield Engines. Alchemy’s proprietary yield engines for gold and USD are designed to power institutional products targeting competitive returns by bridging traditional and decentralized markets.

Self-Custody for Retail. A planned self-custody retail wallet is designed to give users direct access to gold-linked payments, yield and DeFi applications while keeping control of their own assets.

“Stablecoins have proven the demand for digital money. The next question is what that money is anchored to,” said Simon Rahme, Co-Founder and CTO, BullionFX | Alchemy. “We engineered Alchemy’s Layer 2 so that gold sits inside the settlement layer itself rather than on top of it. That gives developers and institutions a base for payments, lending and yield products, with reserves designed to be verifiable on-chain.”

Transaction Terms

Under the LOI, which contains certain binding provisions, the parties will work toward definitive agreements. The transaction, if consummated, will result in significant issuance of Amaze common stock to BullionFX. Final terms are subject to due diligence, regulatory review, approval by each party’s board of directors and other customary closing conditions.

About Amaze Holdings, Inc. (NYSE American: AMZE)

Amaze Holdings, Inc. is an end-to-end, creator-powered commerce platform offering tools for brand development, product creation, advanced e-commerce, audience growth and scalable managed services. By helping people turn what they know, create and share into sustainable income, Amaze enables creators to build deeper audience relationships and more flexible paths to a better life. Discover more at www.amaze.co.

Cautionary Note Regarding Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, including statements regarding the proposed acquisition of the BullionFX Assets; the anticipated benefits, capabilities and potential of those assets; the parties’ ability to negotiate and enter into definitive agreements; the ability to successfully integrate the BullionFX Assets and realize anticipated synergies and value creation; the ability to generate anticipated yields or returns from proprietary yield engines or other platform features; the timing and success of planned product launches, including the self-custody retail wallet and Stable Asset Treasury vehicle; and expectations regarding the adoption and growth of decentralized finance, stablecoins, and gold-backed digital assets. Forward-looking statements often contain words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “will,” “should,” “could,” “may,” “designed to,” or “targeted.” These statements are based on management’s current views and assumptions and are not guarantees of future performance. Important factors that could cause actual results to differ materially include, without limitation: the ability of the parties to negotiate and execute definitive agreements; the completion of due diligence; the receipt of required regulatory, stockholder and board approvals and the satisfaction of other closing conditions; the occurrence of any event that could give rise to termination; the significant dilution to Amaze stockholders in connection with the transaction; the continued availability of capital and financing; the ability to commercialize and operationalize the BullionFX Assets; Amaze’s lack of operating history in digital asset infrastructure and decentralized finance; the performance and security of blockchain-based technology and digital assets; risks related to smart contract vulnerabilities, software bugs, cyberattacks, hacking incidents, and operational failures affecting blockchain-based systems; evolving federal and state laws, regulations and guidance applicable to digital assets, stablecoins, decentralized finance platforms and related custodial arrangements, including potential classification of tokens as securities; the creditworthiness, performance and regulatory status of third-party custodians holding physical gold reserves; the ability to maintain one-to-one gold backing and real-time attestation as described, and the risk that reserves may not be verified as anticipated; competition from established and emerging participants in the digital asset, stablecoin and decentralized finance industries; the ability to protect and enforce intellectual property rights in the acquired technology; the volatility of cryptocurrency and gold markets; prevailing market, regulatory and business conditions; and other risks and uncertainties described in Amaze’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Amaze undertakes no obligation to update any forward-looking statement except as required by law.

Investor & Media Contact:

Amaze Investor Relations

ir@amaze.co · 888-672-0365

Source: Amaze Holdings, Inc.

Released September 29, 2026

ATLANTA, Sept. 29, 2026 (GLOBE NEWSWIRE) — Acuity Inc. (NYSE: AYI) announces that its Board of Directors has elected Nick Tzitzon as an Independent Director, effective September 24, 2026.

In connection with the appointment, the Board approved an increase in its size from nine to ten directors. Tzitzon will serve on the Audit and Governance Committees, and his initial term will expire at the Company’s next annual meeting of stockholders.

Tzitzon currently serves as Vice Chairman of ServiceNow and leads the company’s AI Institute, where he works with customers, partners and policymakers on the transformative potential of artificial intelligence. He brings extensive experience leading growth, strategy and digital transformation initiatives across the technology sector.

“Nick’s experience helping organizations harness software, data and AI to drive productivity and business outcomes aligns with how we are creating value for customers and shareholders,” said Neil Ashe, Chairman, President and Chief Executive Officer of Acuity. “We are pleased to welcome Nick to the Board and look forward to the perspective he will bring as we advance our strategy.”

“I am honored to join Acuity’s Board of Directors,” said Tzitzon, “Under Neil’s leadership, Acuity is positioned to lead the next wave of AI value creation. Industrial intelligence is a massive global growth opportunity. I’m enthusiastic about the company’s bright future and look forward to supporting the team on that journey.”

About Acuity Inc.

Acuity Inc. (NYSE: AYI) is a market-leading industrial technology company. We use technology to solve problems in spaces, light and more things to come. Through our two business segments, Acuity Brands Lighting (ABL) and Acuity Intelligent Spaces (AIS), we design, manufacture, and bring to market products and services that make a valuable difference in people’s lives.

We achieve growth through the development of innovative new products and services, including lighting, lighting controls, building management solutions, and an audio, video and control platform. We focus on customer outcomes and drive growth and productivity to increase market share and deliver superior returns. We look to aggressively deploy capital to grow the business and to enter attractive new verticals.

Acuity Inc. is based in Atlanta, Georgia, with operations across North America, Europe and Asia. The Company is powered by approximately 13,000 dedicated and talented associates. Visit us at www.acuityinc.com.

Investor Contact: 
Charlotte McLaughlin 
Vice President, Investor Relations 
(404) 853-1456 
investor.relations@acuityinc.com

Media Contact: 
April Appling 
Senior Vice President, Corporate Marketing and Communications 
corporatecommunications@acuityinc.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2ef46fca-56ea-4e4b-950b-9652414dfb6a

Reference is made to SFL Corporation Ltd.’s Second Quarter 2026 Results published on August 26, 2026. Please find attached the Second Quarter 2026 Results, now including the Responsibility Statement, in accordance with Section 5-6 of the Norwegian Securities Trading Act. No other changes have been made to the report. 

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Questions may be directed to SFL Management AS:

Investor and Analyst Contacts:

Aksel Olesen, Chief Financial Officer, +47 23 11 40 36

Espen Nilsen Gjøsund, Vice President – Investor Relations, +47 47 50 05 00
André Reppen, Chief Treasurer & Senior Vice President, +47 23 11 40 55

Media Contact:
Ole B. Hjertaker, Chief Executive Officer, SFL Management AS
+47 23 11 40 11

Attachment

• SFL – Second Quarter 2026 Results corr

November 17 FDA Meeting Could Define the Next Phase for NEO212

DALLAS, Sept. 29, 2026 (GLOBE NEWSWIRE) — (www.InvestorsTape.com) — NeOnc Technologies Holdings (NASDAQ: NTHI) is heading toward another potentially important regulatory milestone, with the U.S. Food and Drug Administration scheduled to meet with the company on November 17, 2026, for an in-person End-of-Phase 1 Type B meeting concerning NEO212, its oral perillyl alcohol-temozolomide conjugate being developed for aggressive central nervous system cancers.

NeOnc plans to seek agency feedback on the proposed patient population, Phase 2 trial design, endpoints, dose selection and the evidence that could ultimately support a future marketing application. The company also intends to discuss potential registrational strategies and whether a future study could potentially support an accelerated-approval pathway.

NEO212 enters that discussion with a completed Phase 1 dose-escalation program and a defined recommended Phase 2 dose of 610 mg, following dose escalation to a protocol-defined maximum tolerated dose of 810 mg. The company has reported early signals of potential activity in heavily pretreated patients, including a patient with recurrent IDH1 wild-type, MGMT-methylated glioblastoma who experienced approximately a 60% tumor reduction and 21 months of disease control. Another heavily pretreated patient with lung cancer metastatic to the brain experienced stable disease for approximately 16 months. These observations remain individual-patient findings rather than controlled evidence of efficacy, making the design and outcome of larger studies critical. NeOnc has also secured UAE IND authorization for NEO212, creating an international clinical-development pathway alongside its U.S. regulatory discussions.

NeOnc CEO Amir Heshmatpour summarized the immediate objective: “This meeting will help us understand FDA’s feedback on the population, study design and endpoints for the next stage of development.” The November meeting follows FDA written feedback earlier this year concerning NEO212’s chemistry, manufacturing and controls program and the planned transition from a capsule to a tablet formulation. That makes the upcoming discussion potentially important not only for clinical strategy, but also for clarifying the practical development path toward a larger study.

The NEO212 story is unfolding alongside meaningful progress from NeOnc’s lead program, NEO100. In August, the company reported topline Phase 2a results in recurrent or progressive Grade III and Grade IV IDH1-mutant glioma, with six-month progression-free survival of 48.9% versus a prespecified 20% benchmark (p=0.0047) and median overall survival of 26.09 months. NeOnc also reported that 86.7% of patients were alive at six months, five of 24 patients remained on treatment at the data cutoff, and one partial response remained ongoing beyond 114 days. The company said it plans to request an FDA Type B meeting to discuss a potential registrational pathway in this setting.

The company has also been building its financial position around those clinical catalysts. In September, NeOnc completed a $15 million registered direct offering priced at $4.20 per share, alongside warrants with a $4.20 exercise price. The financing involved new and existing healthcare-focused institutional investors, with proceeds designated for working capital, general corporate purposes and the redemption of Series A convertible preferred stock. Days later, NeOnc announced that it had redeemed all 6,000 outstanding Series A preferred shares for $6 million in cash, stating that the transaction eliminated the related potential dilution without issuing common shares in the redemption.

There has also been notable insider activity. NeOnc reported in September that its executives had made approximately $629,000 in open-market purchases following the positive NEO100 Phase 2a results, including CEO Amir Heshmatpour’s purchase of an additional 35,000 shares for approximately $115,400 and 111,000 shares purchased by Heshmatpour since the August clinical readout. These purchases are factual disclosures of insider transactions and do not establish future clinical or market performance.

Wall Street has added another layer to the story. Roth Capital analyst Jonathan Aschoff initiated coverage of NeOnc in September with a reported $20 price target, while the research firm identified potential pivotal-trial starts for NEO100 and NEO212 as future development milestones. That is an analyst view rather than a company forecast or regulatory determination.

For NTHI, the November 17 FDA meeting now sits at the center of a broader sequence of catalysts: regulatory feedback for NEO212, continued advancement of NEO100 following its Phase 2a readout, potential registrational discussions, international development in the UAE and further financing and clinical execution.

For investors tracking the CNS biotech space, that makes November 17 a date with potentially significant implications for the company’s development roadmap heading into 2027.

About InvestorsTape.com

At InvestorsTape.com, our mission is simple: deliver financial news that cuts through the noise and shines a spotlight on the companies, innovations, and market forces shaping the next decade of growth. In a landscape dominated by high-frequency headlines and fleeting narratives, we bring clarity, depth, and balance to the stories that matter, helping investors discover high-potential companies and evaluate emerging opportunities with confidence.

Contact
benh@investorstape.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements that may regard NeOnc Technologies Holdings’ future revenue, growth trajectory, profitability outlook, expansion plans, strategic partnerships, potential regulatory approvals, and other projections, plans, and objectives. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including market conditions, timing of venue openings, execution risks, operational performance, competition, regulatory matters, and general economic conditions. Readers should not place undue reliance on these statements, which speak only as of the date made.

General Disclaimer:

InvestorsTape.com has been compensated for press and editorial coverage of NeOnc Technologies Holdings and further disclosure information is available here. This communication is provided for informational and journalistic purposes only and reflects the independent editorial views of InvestorsTape.com.

This editorial discusses investigational therapy and clinical-trial results and is not medical advice or a recommendation to buy or sell securities.

This publication is protected speech under the First Amendment of the United States Constitution. Nothing herein constitutes an offer, solicitation, or recommendation to buy or sell any security, nor should it be construed as investment advice. Investing in securities involves risk, including the possible loss of principal. Readers are encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decision.

On 29 September 2026, Enefit OÜ, wholey owned subsidiary of Eesti Energia AS, officially opened the Kelmė I and Kelmė II wind farms in Lithuania. The projects add a combined 167 MW of renewable electricity generation capacity to Lithuania’s electricity system. Enefit invested approximately EUR 324 million in the development of the wind farms.

The two wind farms are expected to generate approximately 530 GWh of electricity annually, contributing to greater energy security and increasing domestic renewable electricity production in Lithuania.

In addition, Enefit is developing battery energy storage systems with capacities of 16 MW and 18 MW at the Kelmė sites. The company plans to invest more than EUR 30 million in energy storage solutions across its Lithuanian wind farm portfolio, supporting the integration of renewable energy and enhancing the stability and flexibility of the electricity system.

Following the commissioning of Kelmė I and Kelmė II, Enefit operates nine wind farms in Lithuania with a combined installed capacity exceeding 400 MW.

Danel Freiberg
Head of Treasury and Financial Risk Management

Eesti Energia AS
+372 5594 3838 | danel.freiberg@enefit.com
Lelle 22, 11318 Tallinn | www.enefit.com

• 15% savings on Air Canada flight rewards for Aeroplan Credit Cardholders, available to Canadian cardholders as a promotional offer through January 11, 2027, becoming a card benefit on January 12, 2027
• Cardholders will also receive semi-annual Air Canada Flight Benefit through their AC Wallet
• Aeroplan Premium Credit Cardholders will gain access to Maple Leaf Lounges worldwide with one guest, as well as Priority Security lanes at select airports for themselves and up to eight companions travelling on the same reservation
• Aeroplan Credit Cardholders will enjoy a 4th Day Free on eligible car rental redemptions, and a 4th Night Free for hotel redemptions – an ongoing card benefit starting January
• All other existing card benefits remain unchanged

MONTRÉAL, Sept. 29, 2026 (GLOBE NEWSWIRE) — Aeroplan, Canada’s leading loyalty program today announced a major refresh of its Canadian co-branded credit card portfolio with new benefits starting January 12, 2027, designed to elevate the travel journey. The upgrades build on Aeroplan’s category-leading offering, delivering savings to cardholders as they plan, book and enjoy travel.

“A great credit card should be rewarding every time you use it and offer benefits that fit the way you travel,” said Scott O’Leary, Vice President, Loyalty and Product, Air Canada. “With new savings on flights, car and hotel redemptions, along with new features that bring comfort and convenience at the airport, these changes across our Aeroplan Credit Card portfolio are designed to deliver benefits to our members at every stage of the travel journey.”

More Ways to Save When You Travel

Aeroplan is introducing simple, easy-to-use new cardholder benefits across the travel journey:

• 15% Off Flight Rewards: Starting January 12, 2027, all primary Aeroplan Credit Cardholders will save 15% in points when they redeem for Air Canada flight rewards, helping points go further on every trip.
• Air Canada Flight Benefits via AC Wallet: Premium Cardholders will get up to $100 annually toward Air Canada travel, with $50 available twice a year. Core Cardholders will get up to $50 annually toward Air Canada travel, with $25 available twice a year. The first benefit will be available on January 15, 2027.
• A 4th Day Free on Car Rental Redemptions: Building on Aeroplan’s popular 4th Night Free hotel benefit, Aeroplan Credit Cardholders will also get a 4th Day Free when redeeming Aeroplan points for eligible car rentals, as an ongoing card benefit.
• A 4th Night Free on Hotel Redemptions: Previously a limited-time promotion, this benefit will become an ongoing card benefit as of January 12, 2027, allowing Aeroplan Credit Cardholders to redeem points for a 4th Night Free on eligible hotel stays.
• Existing Travel Benefits Continue: Cardholders will continue to enjoy the benefits already included with their eligible cards. All other existing card benefits remain unchanged, including free first checked bags and priority boarding for eligible cards.

New Benefits for Aeroplan Premium Credit Cardholders
Aeroplan Premium Credit Cardholders will enjoy a smooth and comfortable airport experience with new premium benefits, subject to standard access terms:

• Elevated Airport Benefits: A benefit that previously applied only in North America will now extend access for Premium Cardholders, plus one travel companion, to Air Canada Maple Leaf Lounges worldwide. This is in addition to Air Canada Café access currently available at locations across Canada.
• Priority Security Clearance: Premium Cardholders will now have access to dedicated Priority Security lanes at select airports worldwide for themselves and up to eight companions travelling on the same reservation.
• Existing Exclusive Premium Benefits Continue: Premium Cardholders will continue to enjoy many of the benefits they love today, including Priority Check-In, Priority Boarding, Priority Baggage Handling, Priority Airport Standby, 10% Head Start, up to 25,000 Status Qualifying Credits, and more.

Aeroplan Credit Card Benefits for Every Stage of Travel

The Aeroplan Credit Card benefits members know and use today will continue, alongside new benefits across the travel journey. Additional information will be available soon through cardholders’ financial institutions. Aeroplan Credit Cardholders can also continue to earn Aeroplan points on everyday purchases through Aeroplan’s extensive network of partners, including Starbucks, Uber, LCBO and more than 900 Avolta airport retail stores.

These portfolio-wide upgrades are part of Aeroplan’s ongoing commitment to delivering exceptional card benefits that support members throughout their travel journey.

For more details on the new Aeroplan Credit Card benefits, including eligibility requirements and applicable terms and conditions, please visit aircanada.com.

Aeroplan Celebrated at the 2026 Freddie Awards
This year marks Aeroplan’s fourth consecutive winning year at the Freddie Awards, the travel loyalty industry’s most respected honours, based on votes from more than 10 million loyalty members globally. Aeroplan is proud to be recognized for earning several top honours at this year’s Freddie Awards in the Americas region, including Program of the Year, Best Redemption Ability, and Best Promotion for its Accelerate Your Way to Status campaign.

About Aeroplan
Air Canada’s Aeroplan is Canada’s leading travel loyalty program, with more than 10 million active members worldwide. Aeroplan Members can earn or redeem points with over 50 airlines to 1,300+ destinations globally, without blackouts or surcharges. Redeem for one-way short-haul flights starting at 6,000 points, Air Canada Vacations packages, and 9,000+ hotel partner properties, or shop brands like Amazon, Apple, and Dyson via the Aeroplan eStore, with redemptions starting at 3,500 points. To join Aeroplan and start turning daily purchases into points for flights, hotel stays, gifts and more, visit aircanada.com/aeroplan.

About Air Canada
Air Canada is Canada’s largest airline, the country’s flag carrier and a founding member of Star Alliance, the world’s most comprehensive air transportation network. Headquartered in Montréal, Air Canada provides scheduled service directly to more than 180 airports in Canada, the United States and internationally on six continents. It holds a Four-Star ranking from Skytrax. Air Canada’s Aeroplan program is Canada’s premier travel loyalty program, with more than 10 million members worldwide. Members can earn or redeem points on the world’s largest airline partner network of more than 50 airlines, plus through an extensive range of merchandise, hotel and car rental partners. Through Air Canada Vacations, it offers a selection of vacation and Flight & Hotel packages, tours, cruises, car rentals, and experiences. Its freight division, Air Canada Cargo, provides air freight lift and connectivity to hundreds of destinations across six continents using Air Canada’s passenger and freighter aircraft. Air Canada’s climate-related ambition includes a long-term aspirational goal of net-zero greenhouse gas emissions by 2050. For additional information, please see Air Canada’s TCFD disclosure. Air Canada shares are publicly traded on the TSX (AC).

Contacts:        media@aircanada.ca

Internet:        aircanada.com/media

Read our annual report Here

Sign up for Air Canada news: aircanada.com

Media Resources:
Photos
Videos
B-Roll
Articles

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4afe2140-6493-4637-8eca-5e0aef207f2d

Vivos Management is Executing on Plan to Immediately Reduce Overhead by an Estimated $3.6 million Annually While Also Driving Top-Line Revenue

LITTLETON, Colo., Sept. 29, 2026 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea (“OSA”) and other breathing and sleep disorders, today announced execution by management on a restructuring and cost reduction plan aimed at saving an estimated $3.6 million annually, beginning in Q4 2026. Parts of the plan have already been implemented, with additional reductions going into effect October 1, 2026. The primary savings in the plan come from staff reductions, vendor relationship changes, negotiated contract savings, and more. The Company expects the full measure of cuts to take place in the fourth quarter of 2026.

In addition to the announced expense reductions, management has also pursued a number of revenue growth initiatives that are beginning to deliver meaningful financial returns. Consistent with the Company’s previously announced growth, referrals into the Company’s Las Vegas Sleep and Airway Medicine Centers continued to rise approximately 3-fold from the first of June through September 27. Revenue from the recent surge in referrals is expected to begin showing up in the fourth quarter and into 2027.

Additional revenue is expected from the Company’s EEG diagnostic testing and treatment initiative, which has also grown from near zero in May to a projected annualized run rate of between $1.5 and $3.0 million in the fourth quarter. The Company is also executing on a Remote Patient Monitoring (RPM) program that is expected to add to top line revenue at an annualized rate of up to $3.5 million by the first quarter of 2027.

Vivos management is also actively engaged in renegotiating legacy payer contracts to bring them up to market rates. The expected range of revenue impact is between $2.4 million and $5.6 million, with very little associated costs. The full realization of these fee increase are expected in early 2027 and throughout the next six to nine months.

R. Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer, stated, “Our management team is laser focused on all of our restructuring and revenue growth initiatives. Perhaps the most compelling is our ongoing conversions and replacement of legacy IT and software systems and infrastructure that dramatically leverage AI and allow us significant and material labor savings.”

When all of these operational expense reductions and revenue growth initiatives are factored in, Vivos management believes the Company will be on track to meet its stated objective of being cash flow positive by late 2026 or early 2027 and profitable in 2027.

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. (Nasdaq: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the flagship DNA appliance is the first to receive clearance for treating moderate to severe OSA in children.

OSA affects an estimated one billion adults aged 30-69 years old worldwide, yet 80% or more remain undiagnosed and unaware of their condition. These chronic disorders are not just a sleep issue—they are closely linked to many serious chronic health conditions. While the medical community has made strides in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood. As a result, legacy OSA treatments like CPAP are often mechanistic and fail to address the root causes. Vivos CARE oral medical devices are designed to help address anatomical factors often associated with OSA.

Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly..

A 2019 analysis published in The Lancet Respiratory Medicine estimated that approximately 936 million adults aged 30 to 69 worldwide have OSA. Through technology, education, provider partnerships and acquisitions, Vivos seeks to expand access to more comprehensive and personalized OSA diagnosis and treatment.

Vivos calls the use of its appliances and related clinical protocols to treat OSA The Vivos Method, a proprietary, clinically effective solution that is a nonsurgical, noninvasive, and nonpharmaceutical approach designed to address the complex needs of OSA patients, and which provides hope to allow patients to Breathe New Life.

For more information, visit www.vivos.com.

Cautionary Note Regarding Forward-Looking Statements

This press release, including statements of the Company’s management and other parties made in connection therewith, contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning future events. Words such as “may,” “would,” “should,” “expects,” “projects,” “potential,” “intends,” “plans,” “believes,”, “hopes”, “anticipates,” “estimates,” “goal,” “aim,” and variations of such words and similar expressions are intended to identify forward-looking statements.

Forward-looking statements in this press release include, without limitation, statements regarding the anticipated future impact on the Company’s the estimated annual expense savings from the Company’s cost reduction initiatives, including the assumption that such savings will approximate $3.6 million on an annualized basis; the Company’s expectations regarding patient demand and medical referrals; and the Company’s goal of becoming cash flow positive.

These statements involve significant known and unknown risks and are based on assumptions and estimates subject to uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to effectively market or sell products or continue to integrate business from the acquisition and alliance model into its own or otherwise implement sales, marketing, and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos’ products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea diagnosis and treatment sector; (iv) the risk that Vivos may be unable to secure additional financing to continue operations, acquire additional sleep centers practices or enter into management services support affiliations on reasonable terms, or maintain its Nasdaq listing when needed, if at all, (v) the risk that actual cost savings from cost reduction initiatives may be less than estimated or may be offset by transition costs, severance obligations, or operational disruptions, (vi) the risk that restructuring and revenue growth initiatives and reimbursement rate changes may not be as significant as expected, (vii) the risk that patient volume increases may not materialize at the pace or magnitude anticipated, (viii) market and other conditions that could impact Vivos’ business or ability to obtain financing; and (ix) other risk factors described in Vivos’ filings with the Securities and Exchange Commission (the “SEC”), which are available free of charge at www.sec.gov.

Except as required by applicable law, Vivos undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances after the date of this press release.

Vivos Investor Relations Contact:

Jennifer Hauser, Executive Assistant to the CEO
jhauser@vivoslife.com
720-927-3125

• Rapid completion of Part A enrollment underscores strong operational execution and investigator engagement in relapsed or refractory acute myeloid leukemia
• Full Part A population expected to provide important efficacy insights across subjects who relapsed from or were refractory to first line (1L) AML treatment, including intensive 7+3 and venetoclax-based regimens
• Expect final Part A dataset to approximate 50/50 between 1L 7+3 and venetoclax-based regimens
• Absence of cardiotoxicity continues to differentiate Annamycin from conventional anthracyclines

HOUSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it has completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML), with 89 subjects enrolled and an additional subject currently in screening. With Part A enrollment closed, the Company remains on track for its planned comprehensive data readout of Part A in the first quarter of 2027.

The rapid pace of enrollment underscores the significant unmet need in R/R AML as well as strong engagement from investigators and clinical sites participating in MIRACLE. The Company expects the expanded Part A dataset to provide important insight into the potential efficacy of AnnAraC across subjects who have relapsed from or are refractory to different first-line (1L) AML treatment approaches, including subjects previously treated with intensive 7+3 chemotherapy and those previously treated with venetoclax-based regimens. Such treatment approaches associated with 1L patient populations are commonly, while not universally, deemed as “fit” and “unfit”, respectively.

“Completing enrollment in Part A of MIRACLE is an important milestone for Moleculin and a strong demonstration of the operational execution behind this pivotal program,” said Walter Klemp, Chairman and Chief Executive Officer of Moleculin. “We have maintained a rapid pace of enrollment in a global, randomized AML trial and, importantly, remain on track in the first quarter of 2027 for our planned comprehensive data readout – one much deeper in data than our first interim n45 readout. Our focus turns to the maturation and analysis of this substantially larger dataset and what it may tell us about the potential of AnnAraC across distinct and clinically important R/R AML patient populations such as “fit” and “unfit” subjects.”

Mr. Klemp continued, “We are particularly excited about the composition of the additional subjects enrolled in Part A and the opportunity that the full Part A population may provide to better understand efficacy based on prior 1L treatment. We estimate that Part A will end with approximately a 50/50 split between “fit” and “unfit” subjects, compared to a roughly 70/30 split, respectively, in the first 45 subjects in Part A. While we are mindful that this shift in composition to more “unfit” subjects represents a more challenging environment for achieving treatment responses, it should provide valuable insight into Annamycin’s ability to fill critical unmet needs. Lastly, we continue to see a lack of cardiotoxicity in MIRACLE’s blinded data.”

“Completing Part A enrollment reflects the execution of our team and investigators and moves us directly toward what we believe will be one of the most important milestones in Annamycin’s development,” Mr. Klemp added. “We are grateful to the patients and families participating in MIRACLE and to the investigators and clinical teams whose commitment has enabled us to reach this milestone at such a rapid pace. With enrollment complete and the trial on track for a comprehensive Q1 2027 readout, we believe Moleculin is entering a potentially defining period for the MIRACLE program.”

About the MIRACLE Trial

MIRACLE is a pivotal Phase 2/3 study of Annamycin in combination with cytarabine for the treatment of adult subjects with AML who are refractory to, or have relapsed (R/R) after, induction therapy. Part A of the trial is a randomized, double-blind portion of the study that compares two different doses of Annamycin plus cytarabine to a control arm of cytarabine plus placebo, all with just one cycle of therapy.

Importantly, as specified by the MIRACLE protocol, remission rates for all three arms, including the control arm, reflect outcomes measured after only a single cycle of therapy. The most commonly cited historical benchmarks in this setting, including the MIRROS and CLASSIC I studies, as well as Moleculin’s own MB-106 study, permitted multiple cycles of treatment. The Company therefore expects absolute remission rates for both the control and Annamycin arms to be lower than those reported in such multi-cycle datasets and believes the most meaningful comparison is the performance of the Annamycin arms relative to the concurrent, randomized control arm evaluated on the same single-cycle basis.

The comprehensive Part A analysis is expected to evaluate efficacy and safety across the complete randomized population and support selection of the optimal Annamycin dose for advancement into Part B of MIRACLE.

For additional information on the MIRACLE trial, please visit ClinicalTrials.gov and reference Identifier NCT06788756.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), has shown to be an efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company is conducting the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine (also referred to as “Ara-C”), together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway toward a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential efficacy and safety of Annamycin and AnnAraC in R/R AML, expected timing of the comprehensive Part A data readout in Q1 2027, the anticipated composition of the Part A population including the expected approximate 50/50 split between fit and unfit subjects, the potential for Part A data to support dose selection for Part B, and the expectation that interim efficacy trends observed in a limited patient population will be confirmed in the full study population. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com

Two-year agreements support vehicle registration enforcement and establish a citation-based processing fee model in a new state

SALT LAKE CITY, Sept. 29, 2026 (GLOBE NEWSWIRE) — OMNIQ CORP. (OTCQB: OMQS) (“OMNIQ” or the “Company”), a provider of AI-based computer vision solutions, today announced that two Pennsylvania municipalities have selected Q Shield™, its Safe City platform, for vehicle registration enforcement. The agreements mark OMNIQ’s first deployments in Pennsylvania. One is with a borough in the northeast; the other is with a township in the southeast.

Q Shield™ identifies vehicles with suspended, revoked or expired registrations and, at one of the two sites, vehicles without required insurance coverage. It sends potential violations to authorized officers, who review the information and make the final enforcement decision. Officers can review activity remotely, extending coverage along busy roads without remaining stationed at a camera. The platform can also support other public safety alerts and investigations according to an agency’s configuration and authority.

The initial deployments will include a combined 18 cameras across nine intersections along corridors carrying approximately 80,000 vehicles per day, based on PennDOT traffic data. Both projects are expected to go live in 2026. OMNIQ is also in discussions with additional Pennsylvania municipalities.

Under the two-year agreements, OMNIQ will receive a processing fee associated with citations issued following agency review and authorization. The fee model creates a transaction-based recurring revenue opportunity tied to enforcement activity. Both agreements include a six-month evaluation period. Each department retains control over enforcement decisions according to its policies, staffing and applicable law.

“These agreements demonstrate the value and scalability of Q Shield for municipalities seeking to expand public-safety capabilities without proportionally increasing personnel,” said Shai Lustgarten, CEO of OMNIQ. “Pennsylvania represents a new market for the platform and a repeatable transaction-based revenue opportunity for OMNIQ. With two municipalities moving toward deployment and additional communities in discussion, we believe Q Shield can become an important part of our recurring-revenue growth strategy.”

ABOUT OMNIQ

OMNIQ CORP. uses patented and proprietary artificial intelligence to deliver machine vision image processing solutions, including data collection, real-time surveillance and monitoring for supply chain management, homeland security, public safety, traffic and parking management, and access control applications.

Our solutions help clients move people, assets and data safely and securely through airports, warehouses, schools, national borders and other environments.

Our principal solutions include hardware, software, communications, automated management services, technical services and support. Our experienced team helps customers simplify integration and deploy practical solutions across complex operating environments.

Privacy and Data Security Commitment

OMNIQ solutions are built to meet the privacy and data protection requirements of the agencies that use them. License plate data is processed and stored in a private network, and access is limited to authorized personnel at the contracting agency. Data is retained and purged according to the agency’s policy and applicable state law. OMNIQ does not sell plate data or share it with third parties for commercial purposes.

For more information about OMNIQ Corp. and its innovative solutions, please visit www.omniq.com.

INFORMATION ABOUT FORWARD LOOKING STATEMENTS

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

This release contains “forward-looking statements” that include information relating to future events and future financial and operating performance. The words “anticipate,” “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

Examples of forward-looking statements include, among others, statements made in this press release regarding the expected timing of the Pennsylvania deployments, anticipated citation processing fee revenue, and additional municipal agreements. Important factors that could cause these differences include, but are not limited to: fluctuations in demand for the Company’s products, the introduction of new products, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, the Company’s ability to manage credit and debt structures from vendors, debt holders and secured lenders, the Company’s ability to successfully integrate its acquisitions, and other information that may be detailed from time-to-time in OMNIQ Corp.’s filings with the United States Securities and Exchange Commission. Examples of such forward-looking statements in this release include, among others, statements regarding revenue growth, driving sales, operational and financial initiatives, cost reduction and profitability, and simplification of operations. For a more detailed description of the risk factors and uncertainties affecting OMNIQ Corp., please refer to the Company’s recent Securities and Exchange Commission filings, which are available at SEC.gov. OMNIQ Corp. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless otherwise required by law.

Contact

IR@OMNIQ.COM

Company

HAYDEN IR:
Brett Maas
(646) 536-7331
brett@haydenir.com

James Carbonara
(646)-755-7412
james@haydenir.com